Q-omics provides the consensus-scored PCDHGB1 profile across patient tissues and cancer cell-line models. PCDHGB1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHGB1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PCDHGB1 RNA expression shows 15,737 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, HNSC, and THYM as cancer lineages where PCDHGB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHGB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHGB1 survival associations across molecular data types. PCDHGB1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHGB1 RNA expression–survival associations across cancer types. High PCDHGB1 expression shows unfavorable associations in BLCA, CESC, BRCA, UVM, LUAD and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHGB1 RNA expression.
This table summarizes PCDHGB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHGB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHGB1 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BLCA, LUAD and LIHC. The HNSC box plot shows higher PCDHGB1 RNA expression in tumor versus normal tissue (log2 FC = +0.564, t-test p < 0.001).
This table shows molecular features associated with PCDHGB1 in patient tissues and cancer cell lines. In patient samples, PCDHGB1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHGB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
